Teladoc (TDOC) CEO Sells $1,223,250.00 in Stock

Teladoc (NYSE:TDOC) CEO Jason N. Gorevic sold 25,000 shares of the stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $48.93, for a total value of $1,223,250.00. Following the completion of the transaction, the chief executive officer now owns 636,184 shares of the company’s stock, valued at approximately $31,128,483.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Teladoc traded down $0.75, hitting $48.70, on Thursday, Marketbeat reports. 767,772 shares of the company traded hands, compared to its average volume of 1,063,091. Teladoc has a 52 week low of $49.10 and a 52 week high of $49.75. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.15 and a quick ratio of 4.15. The company has a market capitalization of $3.06 billion, a PE ratio of -29.52 and a beta of 0.35.

Teladoc (NYSE:TDOC) last issued its quarterly earnings results on Tuesday, May 1st. The health services provider reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.04. Teladoc had a negative return on equity of 20.40% and a negative net margin of 41.06%. The firm had revenue of $89.64 million during the quarter, compared to the consensus estimate of $86.77 million. During the same period last year, the company earned ($0.30) earnings per share. The company’s revenue was up 109.0% on a year-over-year basis. sell-side analysts anticipate that Teladoc will post -1.37 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of TDOC. SG Americas Securities LLC bought a new position in shares of Teladoc during the fourth quarter valued at $101,000. We Are One Seven LLC increased its holdings in shares of Teladoc by 241.1% during the first quarter. We Are One Seven LLC now owns 2,845 shares of the health services provider’s stock valued at $115,000 after acquiring an additional 2,011 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Teladoc by 68.8% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,874 shares of the health services provider’s stock valued at $116,000 after acquiring an additional 1,171 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Teladoc during the first quarter valued at $154,000. Finally, Montag A & Associates Inc. bought a new position in shares of Teladoc during the fourth quarter valued at $200,000.

A number of research firms have issued reports on TDOC. SunTrust Banks increased their price objective on Teladoc to $48.00 and gave the stock a “positive” rating in a report on Wednesday, May 2nd. Craig Hallum set a $39.00 price objective on Teladoc and gave the stock a “hold” rating in a report on Wednesday, May 2nd. ValuEngine upgraded Teladoc from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Canaccord Genuity reiterated a “buy” rating and issued a $45.00 price objective on shares of Teladoc in a report on Friday, April 13th. Finally, Wells Fargo set a $46.00 price objective on Teladoc and gave the stock a “buy” rating in a report on Friday, April 6th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $42.67.

Teladoc Company Profile

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Insider Buying and Selling by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply